Fig. 4From: Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s diseaseChange from baseline in mean Neuropsychological Test Battery total composite z-score by visit for individual BI 409306 doses and placebo (pooled analysis). BID, twice daily; QD, once daily; SD, standard deviationBack to article page